I just found this post on "The Raging Bull". It discusses one of the aspects as to why Pfizer may have dealt the drug back to Liposome.
If anything, it provides food for thought. Any thoughts?
(From the Raging Bull)
Baker, thanks for your welcome. Happy to be aboard.
You are correct in that the advisory committee's action on a drug app is critical. They are the oncologists "hired" by the FDA to give expert opinion as to a drug's worthiness for approval.
Those in the know feel extremely confident of Evacet's approval. Like Abelcet, Evacet is a lipid (safer) form of an already-approved, widely used drug. Lipo studies prove that Evacet causes significantly less cardiotoxicity. End of story.
As to Pfizer's "giving back" of Evacet to Liposome, and all the wailing about why Pfizer would "give away" a potentially successful product, lets finally get this story straight. Yes, Lipo reaquired Evacet. No, Lipo did not drive over to Pfizer and go, "Pretty please, please, please PUH-LEEZE take pity on us and hand us our drug back!!" There were lots of negotiations and a deal was struck. Pfizer does not give away drugs in development for nothing. One of Pfizer's concerns about Evacet: Pfizer has no oncology sales force. Indeed, they sell no oncology products. To market Evacet themselves, they would have had to hire and train an entirely new sales and sales support division, including managers, professional services, etc. Not to mention the
cost of finishing the studies and the filing costs with the FDA. Pfizer's way too savvy for all that. Lipo and Pfizer struck a deal, and Pfizer is happy.
Moral of story: beware uninformed stock "research" depts and the tales they tell.
Tekno! is llloooooonnggg and loving it. |
